Show simple item record

dc.contributor.authorHajibandeh, Shahin
dc.contributor.authorHajibandeh, Shahab
dc.contributor.authorSutcliffe, Robert P
dc.contributor.authorBartlett, David
dc.date.accessioned2024-10-16T12:55:34Z
dc.date.available2024-10-16T12:55:34Z
dc.date.issued2024-05-31
dc.identifier.citationHajibandeh S, Hajibandeh S, Sutcliffe RP, Bartlett D. Meta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approach. HPB (Oxford). 2024 Sep;26(9):1103-1113. doi: 10.1016/j.hpb.2024.05.015. Epub 2024 May 31.en_US
dc.identifier.issn1365-182X
dc.identifier.eissn1477-2574
dc.identifier.doi10.1016/j.hpb.2024.05.015
dc.identifier.pmid38866629
dc.identifier.urihttp://hdl.handle.net/20.500.14200/6141
dc.description.abstractBackground: To evaluate survival outcomes of pulmonary resection for isolated metachronous pancreatic cancer metastasis. Methods: A systematic search of electronic data sources and reference lists were conducted. Proportion meta-analysis model was constructed to quantify 1- to 5-year survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis. Random-effects modelling was applied to calculate pooled outcome data. Results: Twenty-four retrospective studies were included reporting a total of 168 patients who underwent pulmonary resection for isolated pancreatic cancer metastasis. The nature of the index pancreatic surgery included 65% pancreaticoduodenectomies, 17.5% distal pancreatectomies, 0.5% total pancreatectomy, and 17% unspecified. Adjuvant chemotherapy was given to 88% of the patients. The median disease-free interval was 35 (8-96) months. The type of pulmonary resection included 54% wedge resections, 26% lobectomies, 4% segmentectomies, 1% pneumonectomies, and 15% unspecified. Pulmonary resection was associated with 1-year survival of 91.1% (95% CI 86.6%-95.5%), 2-year survival of 77.5% (95% CI 68.9%-86.0%), 3-year survival of 65.0% (95% CI 50.7%-79.3%), 4-year survival of 52.0% (95% CI 37.2%-66.9%), and 5-year survival of 37.0% (95% CI 25.0%-49.1%). Conclusion: Pulmonary resection for isolated pancreatic cancer metastasis is associated with acceptable overall patient survival. We recommend selective pulmonary resection for isolated pulmonary metastasis from pancreatic cancer. Our findings may encourage conduction of better-quality studies in this context to help establishment of definitive treatment strategies.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.hpbonline.org/en_US
dc.rightsCopyright © 2024 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
dc.subjectOncology. Pathology.en_US
dc.subjectSurgeryen_US
dc.subjectGastroenterologyen_US
dc.titleMeta-analysis of survival after pulmonary resection for isolated metachronous pancreatic cancer metastasis: a promising, albeit infrequent, approachen_US
dc.typeArticleen_US
dc.source.journaltitleHPBen_US
dc.source.volume26
dc.source.issue9
dc.source.beginpage1103
dc.source.endpage1113
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorSutcliffe, Robert
dc.contributor.trustauthorBartlett, David
dc.contributor.departmentLiveren_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.affiliationUniversity Hospitals of North Midlands NHS Trust; Swansea Bay University Health Board; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trusten_US
oa.grant.openaccessnaen_US


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record